ATC Group: L02AE02 Leuprorelin

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L02AE02 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L02 Endocrine therapy
3 L02A Hormones and related agents
4 L02AE Gonadotropin releasing hormone analogues
5 L02AE02 Leuprorelin

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Code Route Amount Notes
PAREN Parenteral 1 mg
PAREN Parenteral 134 mg (depot)
SC Subcutaneous 60 ug (implant)

Active ingredients in L02AE02

Active Ingredient

Leuprorelin is inactive when given orally due to poor membrane permeability and an almost complete inactivation by intestinal proteolytic enzymes. Leuprorelin has potent LHRH agonist properties when given during short-term and intermittent therapy, however, when administered in a continuous, nonpulsatile manner, LHRH analogs induce inhibition of gonadotropin secretion and suppression of testicular steroidogenesis.

Related product monographs

Document Type Information Source  
 CAMCEVI Prolonged-release suspension for injection MPI, EU: SmPC European Medicines Agency (EU)
 LECTRUM Powder for suspension for injection MPI, EU: SmPC Marketing Authorisation Holder
 LUCRIN Depot Solution for injection MPI, Generic Health Products Regulatory Authority (ZA)
 LUPRON DEPOT Powder for solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)
 LUTRATE DEPOT Powder and solvent for prolonged-release suspension for injection MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 PROSTAP 3 DCS Powder and solvent for suspension for injection in pre-filled syringe MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)

United States medicines

Medicines classified under this ATC code globally

Australia (AU)

Austria (AT)

Brazil (BR)

Canada (CA)

Croatia (HR)

Cyprus (CY)

Ecuador (EC)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Lithuania (LT)

Malta (MT)

Mexico (MX)

Netherlands (NL)

New Zealand (NZ)

Poland (PL)

Romania (RO)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.